Document Detail


Hemostatic therapy for the treatment of intracranial hemorrhage.
MedLine Citation:
PMID:  18363532     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intracranial hemorrhage results in poor neurologic outcomes and high mortality. Current management is limited to supportive care. In addition to the initial bleeding event, rebleeding and hematoma expansion have been identified as major risk factors for poor outcomes in these patients. The antifibrinolytic agents tranexamic acid, aminocaproic acid, and recombinant activated factor VII (rFVIIa) have been studied with the hopes of achieving early hemostasis and improving outcomes. Available data suggest that tranexamic acid and aminocaproic acid are more harmful than beneficial for this indication; therefore, they have no role in the treatment of intracranial bleeding. Alternatively, rFVIIa, has shown promising results in the management of spontaneous intracerebral hemorrhage. Clinicians should be aware of the available evidence regarding the use of these hemostatic agents in the management of intracranial hemorrhage, including traumatic brain injury, intracerebral hemorrhage, and subarachnoid hemorrhage.
Authors:
Xi Liu-DeRyke; Denise Rhoney
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  28     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-26     Completed Date:  2008-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  485-95     Citation Subset:  IM    
Affiliation:
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. xi.liu@pharm.utah.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aminocaproic Acids / therapeutic use
Antifibrinolytic Agents / therapeutic use
Brain Injuries / drug therapy*,  epidemiology
Clinical Trials as Topic
Factor VIIa / therapeutic use
Hemostatics / therapeutic use*
Humans
Intracranial Hemorrhages / drug therapy*,  epidemiology
Recombinant Proteins / therapeutic use
Tranexamic Acid / therapeutic use
Chemical
Reg. No./Substance:
0/Aminocaproic Acids; 0/Antifibrinolytic Agents; 0/Hemostatics; 0/Recombinant Proteins; 0/recombinant FVIIa; 1197-18-8/Tranexamic Acid; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of hypertonic saline for the management of intracranial hypertension after stroke and traumatic...
Next Document:  Effectiveness of probiotics in the treatment of irritable bowel syndrome.